<DOC>
	<DOCNO>NCT00980187</DOCNO>
	<brief_summary>The aim study evaluate effect indapamide SR 1.5 mg blood pressure , blood test ( glucose metabolism , lipid , mineral , uric acid ) , cardiac function , endothelial arterial function , comparison hydrochlorothiazide 25 mg , patient hypertension type 2 diabetes mellitus . In order achieve good control blood pressure patient , diuretic treatment add ACE inhibitor ( quinapril 10-40 mg/day ) . Therefore , eventually , study provide data comparison combination indapamide SR 1.5 mg + quinapril versus hydrochlorothiazide 25 mg + quinapril .</brief_summary>
	<brief_title>A Comparison Indapamide SR 1.5 mg With HCTZ 25 mg , Combination With ACE-inhibitor , Patients With Mild Moderate AHT Type 2 DM</brief_title>
	<detailed_description>Hypertension treatment patient type 2 diabetes mellitus still difficult clinical problem . New European American guideline recommend target blood pressure le 130/80 mmHg . Indeed , show Hypertension Optimal Treatment study ( HOT study ) reduce diastolic blood pressure 81 mm Hg instead 84 mm Hg , number major cardiovascular event reduce 51 % . However , 25 % patient hypertension diabetes reach target 130/80 mm Hg routine clinical practice . Therefore , combination therapy always recommend ( 8 , 9 ) . This include diuretic ; however , none two guideline make recommendation regard best diuretic therapy hypertensive patient diabetes . Indapamide diuretic special characteristic , show experimental study provide cardio- renal- protection hypertensive patient . In time similar antihypertensive effect amlodipine hydrochlorothiazide . Intrinsic mechanism probably related antioxidant property , also action calcium channel . Moreover , compare hydrochlorothiazide , indapamide adverse effect lipid metabolism seem negative impact renal function . However , recent study patient hypertension diabetes suggest superiority indapamide hydrochorothiazide different metabolic parameter . Therefore , new research look detail comparison two diuretic mandatory . The aim study evaluate effect indapamide SR 1.5 mg blood pressure , blood test ( glucose metabolism , lipid , mineral , uric acid ) , cardiac function , endothelial arterial function , comparison hydrochlorothiazide 25 mg , patient hypertension type 2 diabetes mellitus . In order achieve good control blood pressure patient , diuretic treatment add ACE inhibitor ( quinapril 10-40 mg/day ) . Therefore , eventually , study provide data comparison combination indapamide SR 1.5 mg + quinapril versus hydrochlorothiazide 25 mg + quinapril . The study conduct accord Prospective , parallel , Randomized , active-controlled , Open , Blinded Endpoint evaluation ( PROBE design ) , one centre , least 50 male female patient mild moderate hypertension type 2 diabetes mellitus , total period 18 month ( 12 month enrollment 6 month follow-up ) . Patients meet inclusion exclusion criterion randomize 1:1 use permute block design . They receive ascend number 1 50 . The investigator ( ) perform analyze echocardiogram , central laboratory measure BNP blood test blind patient medication . Patients randomize either indapamide prolonged-release 1.5 mg/day hydrochlorothiazide 25 mg/day , give orally . Quinapril add begin study allow consistent blood pressure control . Dose quinapril titrate 10 mg/day 15 mg/day , 20 mg/day , 40 mg/day , need blood pressure control . The treatment administer randomized patient 6 month . Assignment study medication perform randomization process . The patient receive medication Investigator/Co-investigator every visit schedule ; ask return , every visit schedule , unused medication empty box , order verify compliance treatment . A treatment compliance 80-120 % consider satisfactory study . If compliance limit mention , investigator decide withdrawal patient study . In exceptional situation , treatment interrupted period maximum 3 day , without withdrawal patient study . The administration study medication document appropriate source document CRF certify Investigator .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Indapamide</mesh_term>
	<criteria>Only diabetic patient present follow criterion enrol study : Aged 18 75 year . Daytime ambulatory blood pressure &gt; 135 and/or &gt; 85 mm Hg ( mild moderate hypertension include study ) , type 2 diabetes mellitus . The blood pressure monitoring device instal visit 0 ( Screening ) conclusion monitoring evaluate Visit1 , randomization . Sinus rhythm . Ability understand full nature purpose study , include possible risk side effect ; ability cooperate Investigator/Coinvestigator , comply requirement study . Any antihypertensive medication stop least two week prior randomisation . Informed write consent give initiation prestudy screen . Secondary hypertension Severe hypertension ( ≥ 180 and/or ≥110 mm Hg ) ; stage III hypertension ( WHO classification ) Symptoms congestive heart failure ( NYHA II IV ) leave ventricular global systolic dysfunction ( EF &lt; 40 % ) Ventricular aneurysm extensive wall motion abnormality Recent ( &lt; 6 month ) myocardial infarction Recent ( &lt; 3 month ) plan coronary revascularization : PCI ( percutaneous coronary intervention ) /CABG ( coronary artery bypass graft ) Severe valvular heart disease/congenital heart disease Hypertrophic cardiomyopathy Pericarditis Chronic cor pulmonale Recent ( &lt; 6 month ) cerebrovascular ischemic symptom ( e.g . transient ischemic accident , prolong reversible ischemic neurological deficit , stroke ) Creatinine level &gt; 1.5 mg/dl men &gt; 1.4 mg/dl woman Pregnancy patient plan become pregnant study period ( female subject ) . Breastfeeding woman Presence history relevant medical condition , include : cancer , HIV , significant disease renal , hepatic , gastrointestinal , respiratory , endocrine , locomotor system , significant metabolic , haematological , neurological disorder History hypersensitivity indapamide , quinapril , thiazides component product ; contraindication study medication Significant acute illness within 14 day prior randomisation Any history drug alcohol abuse , recent psychiatric disorder use psychotropic substance Any current condition disease know interfere significantly absorption , distribution , metabolism excretion study drug Current use hormonal contraceptive drug ( female subject ) ; nonhormonal contraceptive measure use , female patient childbearing potential , follow : diaphragm , male condom , intrauterine device , tube ligation , selective tube occlusion procedure , vasectomy partner Participation another investigational study last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>blood test</keyword>
	<keyword>cardiac function</keyword>
	<keyword>endothelial function</keyword>
	<keyword>arterial function</keyword>
</DOC>